Total Funding
52
26
Total FundingGrant raised
Growth Score
-7 pts
Heat Score
-1 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
See more interactive data and historical milestones on desktop for the best experience
33062
BioVectra offers contract development and manufacturing capacity for intermediates and active pharmaceutical ingredients.
Acquired by 
Agilent Technologies
- Regis Duffy: Founder
- Heather Delage: Chief Commercial OfficerPast Role: BioVectra, Vice President, Business Development and General Manager, Windsor Site
Mallinckrodt
About the Company
BioVectra manufactures ingredients for global pharmaceutical and biotechnology clients offering therapeutics used in the treatment of cancer, kidney disease, cardio-vascular disease, multiple sclerosis, and many other serious diseases. With over 40 years experience, the company is proficient in synthetic organic chemistry, fermentation of chemical
and biologic molecules, downstream processing, MPEG production, and conjugation chemistry.
BioVectra was founded on 1970 and is based in Charlottetown, Canada.
